We use cookies to ensure that we give you the best experience on our website Learn more

My documents

Sep 11, 2018

ERC congress - Resuscitation 2018

2 - Neuropsychological outcome after cardiac arrest: Rationale and description of a sub-study of The Target Temperature Management 2 Trial






Background: Brain injury is the primary cause of mortality and morbidity in resuscitated cardiac arrest. This abstract describes a planned study designed to provide detailed and longitudinal information on cognition after out-of-hospital cardiac arrest (OHCA) and its relationship to associated factors as emotional function, fatigue, and sleep. There is a lack of longitudinal studies examining several cognitive domains post-cardiac arrest. A secondary aim is to utilize this information to validate a neurocognitive screening battery used 6 months after OHCA in the large pragmatic Target Temperature Management 2 Trial (TTM2-trial), assessing effectiveness of controlled hypothermia after OHCA. This screening battery could be practical to include in routine follow-up. Methods/design: This longitudinal multi-center clinical study is a sub-study of the TTM2-trial. Approximately 7 and 24 months after OHCA, survivors (n≈100) at selected study sites will perform a standardized neuropsychological assessment including performance-based tests of cognition and questionnaires of behavioral and emotional function, fatigue, and insomnia. At 1:1 ratio, a control group of myocardial infarction (MI) patients but no occurrence of cardiac arrest will be recruited and perform the same test battery. Group differences at 7 and 24 months will be analyzed per cognitive domain (verbal, visual/constructive, short-term working memory, episodic memory, processing speed, executive functions). Results of the OHCA survivors on the TTM2 neurocognitive screening battery will be compared with neuropsychological test results at 7 months time. This study starts in summer 2018. OHCA and MI patients are adjacently included. Conclusion: This sub-study of the TTM2-trial will provide detailed knowledge on cognitive impairment from a holistic perspective after OHCA. This, along with validating the shorter neurocognitive screening used in the main TTM2-trial, will make unique and important information available that may be used to guide clinical trials, inform patients and families, and design rehabilitation programs.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.



Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.